Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding the efficacy of its drug candidate, sonelokimab (SLK), which reportedly failed to meet clinical benchmarks [1][3][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotech firm based in Zug, Switzerland, focusing on next-generation immunotherapies [2]. Legal Proceedings - The lawsuit is on behalf of investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, with a deadline of December 15, 2025, for investors to seek lead plaintiff status [1][2]. Drug Candidate Details - MoonLake promoted SLK as a breakthrough treatment due to its Nanobody structure but allegedly failed to disclose that it targets the same molecules as BIMZELX, an FDA-approved monoclonal antibody, indicating it was not clinically superior [3]. Trial Results and Market Impact - On September 28, 2025, MoonLake disclosed that SLK did not meet efficacy benchmarks in Phase 3 trials, leading to a significant stock price decline of $55.75 per share, nearly 90%, in one trading session [4].

Core Viewpoint - MoonLake Immunotherapeutics (MLTX) is facing securities fraud allegations after a significant stock price drop of nearly 90%, prompting investors to seek legal recourse [1][3]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company was conducting Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa (HS) [4]. Group 2: Allegations and Legal Action - A lawsuit has been filed against MoonLake and its senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - The complaint claims that MoonLake misrepresented its clinical data and the advantages of its Nanobody structure over competitors, which undermined the drug's regulatory approval and commercial viability [6]. Group 3: Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock plummeted from $61.99 per share to $6.24 per share, a decline of $55.75 or nearly 90% [7].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased common stock of MoonLake between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The deadline to move the court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [4]. Group 2: Legal Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [5]. Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to significant stock price decline [2][5][6][8]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake to contact them for discussing legal options [1]. - There is a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against MoonLake [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [5]. - Specific allegations include misleading claims about SLK's clinical benefits and its supposed superiority over BIMZELX, which were not supported by evidence [5]. - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 [6][8].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with investors having until December 15, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [3]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a superior clinical response for patients compared to competitors [4]. Group 3: Clinical Trial Results - The VELA Phase 3 trials for sonelokimab reported disappointing results, with VELA-2 failing to meet its primary endpoint, raising concerns about the drug's regulatory approval and commercial viability [5][6]. - Following the announcement of the trial results on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from March 10, 2024, to September 29, 2025 [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including being ranked No. 1 for the number of settlements in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake made false and misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of misleading statements and failure to disclose material facts regarding its product SLK, which led to significant stock price decline [2][5][6]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake to discuss their legal options, particularly those who acquired securities between March 10, 2024, and September 29, 2025 [1][2]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [2][8]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false and misleading statements about the efficacy of SLK compared to BIMZELX, including claims about molecular targets and clinical benefits [5]. - Specific allegations include that SLK's distinct Nanobody structure does not provide superior clinical benefits over traditional monoclonal antibodies and that its supposed increased tissue penetration does not translate to clinical efficacy [5]. Group 3: Stock Price Impact - Following the announcement of disappointing results from the Phase 3 VELA program, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [6][7].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [2][4][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic for moderate to severe hidradenitis suppurativa [5]. Allegations and Claims - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, alleging that MoonLake misrepresented its clinical data and the benefits of its Nanobody structure compared to traditional monoclonal antibody treatments [4][6][7]. - The complaint suggests that the company's claims about "strong clinical data" and differentiation from competitors were misleading [6][7]. Stock Performance - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].

Core Viewpoint - MoonLake Immunotherapeutics has faced a significant decline in share price, dropping nearly 90% due to disappointing Phase 3 trial results for its drug candidate sonelokimab (SLK) [1][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing sonelokimab (SLK) for treating moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease [3]. Legal Issues - A securities fraud class action lawsuit has been filed against MoonLake in the U.S. District Court for the Southern District of New York, alleging that the company and certain executives made materially false and misleading statements regarding SLK's clinical prospects [2][4]. - The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline set for December 15, 2025 [2]. Trial Results and Market Reaction - The VELA Phase 3 trials for SLK reported disappointing results, with one trial failing to meet its primary endpoint and the efficacy results from the successful trial being significantly lower than those of the competitor drug BIMZELX [4][5]. - Following the announcement of the trial results, MoonLake's stock price fell from $61.99 to $6.24, a decrease of $55.75 per share, which analysts described as a "disastrous result" [5]. Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors by exaggerating SLK's advantages over competitors, particularly its unique "Nanobody" structure, which was suggested to provide superior efficacy compared to traditional monoclonal antibodies [4][6]. - Plaintiffs argue that the company's promotion of SLK as a potential "gold standard" treatment was misleading and contributed to an artificial inflation of the stock price during the class period [6].

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 21, 2025 2:16 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 21, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Pe ...